Significance of fractional exhaled nitric oxide in chronic eosinophilic pneumonia: a retrospective cohort study

BMC Pulmonary Medicine

Choon-Taek Lee¹  Jae Ho Lee¹  Ho Il Yoon¹  Young-Jae Cho¹  Jong Sun Park¹  Yeon Joo Lee¹  Hongyeul Lee¹  Taehoon Lee¹  Ji Young Park¹ 

[1] Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea

关键词: Corticosteroid;    Biomarker;    Fractional exhaled nitric oxide;    Chronic eosinophilic pneumonia;   

Others  :  862931
DOI  :  10.1186/1471-2466-14-81

 received in 2014-04-05, accepted in 2014-05-06,  发布年份 2014

【 摘 要 】

Background

Chronic eosinophilic pneumonia (CEP) is characterized by chronic eosinophilic infiltration of the lung. It is dramatically responsive to corticosteroid treatment, but symptoms and radiopacities recur frequently after tapering or discontinuing the medication. Fractional exhaled nitric oxide (FeNO) is a well-known noninvasive marker of eosinophilic airway inflammation. The aim of this retrospective cohort study was to investigate the relationships of FeNO with peripheral eosinophilia and the clinical state of CEP and its validity for predicting exacerbation of CEP.

Methods

Standard clinical and laboratory parameters, peripheral eosinophil percentage and count, and FeNO level were measured in 18 patients with CEP at several assessment points over 1 year.

Results

FeNO level was positively correlated with peripheral eosinophil count (r = 0.341, P = 0.005) and percentage (r = 0.362, P = 0.003). The median (IQR) FeNO levels were 79 (41–88) and 35 (26–49) ppb in uncontrolled (13/74 measurements) and controlled (61/74 measurements) CEP, respectively (P = 0.010). The FeNO level of 66.0 ppb showed the largest area under the curve (0.835) for predicting exacerbation of CEP (sensitivity = 0.80, specificity = 0.84).

Conclusion

FeNO may be useful for monitoring eosinophilic parenchymal inflammation and determining the appropriate corticosteroid dose in CEP.

【 授权许可】

   
2014 Park et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Marchand E, Reynaud-Gaubert M, Lauque D, Durieu J, Tonnel AB, Cordier JF: Idiopathic chronic eosinophilic pneumonia. A clinical and follow-up study of 62 cases. The Groupe d’Etudes et de Recherche sur les Maladies “Orphelines” Pulmonaires (GERM“O”P). Medicine (Baltimore) 1998, 77(5):299-312.
• [2]Naughton M, Fahy J, FitzGerald MX: Chronic eosinophilic pneumonia. A long-term follow-up of 12 patients. Chest 1993, 103(1):162-165.
• [3]Alam M, Burki NK: Chronic eosinophilic pneumonia: a review. South Med J 2007, 100(1):49-53.
• [4]Oh MJ, Lee JY, Lee BJ, Choi DC: Exhaled nitric oxide measurement is useful for the exclusion of nonasthmatic eosinophilic bronchitis in patients with chronic cough. Chest 2008, 134(5):990-995.
• [5]Berlyne GS, Parameswaran K, Kamada D, Efthimiadis A, Hargreave FE: A comparison of exhaled nitric oxide and induced sputum as markers of airway inflammation. J Allergy Clin Immunol 2000, 106(4):638-644.
• [6]Payne DN, Adcock IM, Wilson NM, Oates T, Scallan M, Bush A: Relationship between exhaled nitric oxide and mucosal eosinophilic inflammation in children with difficult asthma, after treatment with oral prednisolone. Am J Respir Crit Care Med 2001, 164(8 Pt 1):1376-1381.
• [7]Warke TJ, Fitch PS, Brown V, Taylor R, Lyons JD, Ennis M, Shields MD: Exhaled nitric oxide correlates with airway eosinophils in childhood asthma. Thorax 2002, 57(5):383-387.
• [8]Knuffman JE, Sorkness CA, Lemanske RF Jr, Mauger DT, Boehmer SJ, Martinez FD, Bacharier LB, Strunk RC, Szefler SJ, Zeiger RS, Taussig LM: Phenotypic predictors of long-term response to inhaled corticosteroid and leukotriene modifier therapies in pediatric asthma. J Allergy Clin Immunol 2009, 123(2):411-416.
• [9]Smith AD, Cowan JO, Brassett KP, Filsell S, McLachlan C, Monti-Sheehan G, Herbison GP, Taylor DR: Exhaled nitric oxide: a predictor of steroid response. Am J Respir Crit Care Med 2005, 172(4):453-459.
• [10]Donohue JF, Jain N: Exhaled nitric oxide to predict corticosteroid responsiveness and reduce asthma exacerbation rates. Respir Med 2013, 107(7):943-952.
• [11]Michils A, Baldassarre S, Van Muylem A: Exhaled nitric oxide and asthma control: a longitudinal study in unselected patients. Eur Respir J 2008, 31(3):539-546.
• [12]Petsky HL, Cates CJ, Lasserson TJ, Li AM, Turner C, Kynaston JA, Chang AB: A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils). Thorax 2012, 67(3):199-208.
• [13]Smith AD, Cowan JO, Brassett KP, Herbison GP, Taylor DR: Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med 2005, 352(21):2163-2173.
• [14]Guo FH, De Raeve HR, Rice TW, Stuehr DJ, Thunnissen FB, Erzurum SC: Continuous nitric oxide synthesis by inducible nitric oxide synthase in normal human airway epithelium in vivo. Proc Natl Acad Sci U S A 1995, 92(17):7809-7813.
• [15]Lee JE, Rhee CK, Lim JH, Lee SM, Shim YS, Lee CT, Lee SW: Fraction of exhaled nitric oxide in patients with acute eosinophilic pneumonia. Chest 2012, 141(5):1267-1272.
• [16]Cho YJ, Lim HJ, Park JS, Lee JH, Lee CT, Yoon HI: Measurement of fractional exhaled nitric oxide in stable bronchiectasis. Tuberc Respir Dis 2013, 74(1):7-14.
• [17]American Thoracic Society, European Respiratory Society: ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med 2005, 171(8):912-930.
• [18]Travers J, Marsh S, Aldington S, Williams M, Shirtcliffe P, Pritchard A, Weatherall M, Beasley R: Reference ranges for exhaled nitric oxide derived from a random community survey of adults. Am J Respir Crit Care Med 2007, 176(3):238-242.
• [19]Sandrini A, Taylor DR, Thomas PS, Yates DH: Fractional exhaled nitric oxide in asthma: an update. Respirology 2010, 15(1):57-70.
• [20]Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg JO, Olin AC, Plummer AL, Taylor DR: An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med 2011, 184(5):602-615.
• [21]Durieu J, Wallaert B, Tonnel AB: Long-term follow-up of pulmonary function in chronic eosinophilic pneumonia. Groupe d’Etude en Pathologie Interstitielle de la Societe de Pathologie Thoracique du Nord. Eur Respir J 1997, 10(2):286-291.
• [22]Barreto M, Villa MP, Monti F, Bohmerova Z, Martella S, Montesano M, Darder MT, Ronchetti R: Additive effect of eosinophilia and atopy on exhaled nitric oxide levels in children with or without a history of respiratory symptoms. Pediatr Allergy Immunol 2005, 16(1):52-58.
• [23]Strunk RC, Szefler SJ, Phillips BR, Zeiger RS, Chinchilli VM, Larsen G, Hodgdon K, Morgan W, Sorkness CA, Lemanske RF Jr: Relationship of exhaled nitric oxide to clinical and inflammatory markers of persistent asthma in children. J Allergy Clin Immunol 2003, 112(5):883-892.
• [24]Fitzpatrick AM, Gaston BM, Erzurum SC, Teague WG: Features of severe asthma in school-age children: Atopy and increased exhaled nitric oxide. J Allergy Clin Immunol 2006, 118(6):1218-1225.
• [25]Jones SL, Kittelson J, Cowan JO, Flannery EM, Hancox RJ, McLachlan CR, Taylor DR: The predictive value of exhaled nitric oxide measurements in assessing changes in asthma control. Am J Respir Crit Care Med 2001, 164(5):738-743.
• [26]Szefler SJ, Wenzel S, Brown R, Erzurum SC, Fahy JV, Hamilton RG, Hunt JF, Kita H, Liu AH, Panettieri RA Jr, Schleimer RP, Minnicozzi M: Asthma outcomes: biomarkers. J Allergy Clin Immunol 2012, 129(3 Suppl):S9-S23.
• [27]Kapande KM, McConaghy LA, Douglas I, McKenna S, Hughes JL, McCance DR, Ennis M, Shields MD: Comparative repeatability of two handheld fractional exhaled nitric oxide monitors. Pediatr Pulmonol 2012, 47(6):546-550.